Amgen has announced the groundbreaking of its newest biomanufacturing facility in North Carolina.
Amgen announced on March 7, 2022 the groundbreaking of its new biomanufacturing facility, located in Holly Springs, NC, that is expected to be operational by 2025. The facility will support the growing demand for medicines that treat serious illnesses such as cancer and heart disease. The new facility will produce a wide range of medicines, utilizing new technologies to maximize efficiency and quality.
"For over four decades, Amgen has been an innovative leader in the manufacturing of complex biologics. Our commitment to continuous improvement and our significant investments in new technologies have enabled us to further accomplish our mission to serve patients while science rapidly evolves," said Robert A. Bradway, chairman and CEO of Amgen, in a press release. "We are delighted to be building our newest facility in North Carolina, a major hub for biopharmaceutical innovation."
The facility will be environmentally conscious, focusing on reducing water usage and waste. Amgen is also focused on increasing diversity in the workplace through the OneTen Coalition, which it is a founding member of. The Coalition’s goal is to change the employment paradigm for black people in the United States. “To achieve this goal, Amgen will work with businesses, educational institutions, and training partners to better develop, retain, and advance diverse talent, focusing on Black Americans without four-year college degrees,” the company said in the press release.
Source: Amgen
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.